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Abstract An MMLV-based retroviral vector containing the 
chloramphenicol acetyl transferase reporter gene under the con- 
trol of a glucose-dependent internal promoter derived from the 
L-type pyruvate kinase gene was constructed. After transfection 
into psi-CRIP packaging cells, clones producing recombinant 
retrovirus were selected. These retroviruses were used to infect 
cultured established hepatocytic ells whose endogenous L-type 
pyruvate kinase gene is transcriptionally regulated by glucose. In 
the infected cells, the reporter gene was as responsive to glucose 
as the endogenous L-type pyruvate kinase gene, and the glucose 
gene activation was time- and concentration-dependent. The pos- 
sibility to confer a glucose responsiveness on a transgene carried 
by a retroviral vector provides a powerful tool in the prospect of 
gene therapy for diabetes mellitus. 
Key words." Retroviral vector; Gene therapy; 
Glucose responsiveness; Hepatocytic ell 
1. Introduction 
Glucose is a modulator of gene expression in practically all 
forms of life. In vertebrates, it especially regulates insulin pro- 
duction in pancreas fl cells (at both transcription and secretion 
levels) and activity of various metabolism enzymes in hepato- 
cytes and adipocytes [1]. Some of these effects are mediated by 
insulin while others require the presence of glucose itself. For 
instance, genes encoding proteins of the glycolytic and lipo- 
genic pathways respond to glucose through a glucose response 
element first characterized in the promoter of the L-type py- 
ruvate kinase (L-PK) gene [2~], and further described in the 
regulatory regions of several other genes [5-7]. 
The L-PK gene glucose response lement (GlRE-position bp 
-168 to -144) is a perfect palindrome composed of two non- 
consensus binding sites for proteins of the MLTF/USF family, 
separated by 5 bp. The L-PK promoter is constituted of this 
GIRE which cooperates with a contiguous hepatocyte nuclear 
factor 4 (HNF4) binding site [2,8], and, in a more proximal 
position (bp -96 to -68), a hepatocyte nuclear factor 1 (HNF1) 
binding site which is essential for a tissue-specific a tivity of the 
L-PK promoter [9,10]. In hepatocytes, the glucose-dependent 
activation of the L-PK gene requires the presence of insulin, 
needed to induce the liver-specific glucose-phosphorylating e - 
zyme, glucokinase [11]. In the cultured mhAT3F cell line, de- 
rived from a transgenic mice expressing the SV40 large T anti- 
gen under the control of the antithrombin III gene promoter 
[12,13], the glucose responsiveness of the L-PK gene does not 
require insulin, probably because, in these cells, glucokinase is
*Corresponding author. Fax: (33) (1) 44 41 24 21. 
replaced by other types of insulin-independent hexokinases 
[11,14]. 
Our purpose was to construct a vector able to transfer into 
cells glucose-responsive genes. We first tested the efficiency of 
the L-PK promoter used as an internal promoter in an en- 
hancerless retroviral vector in conferring a glucose responsive- 
ness on the chloramphenicol acetyl transferase (CAT) reporter 
gene at physiological concentrations. Besides, we observed that 
in mhAT3F cells infected with such a recombinant retrovirus, 
activations of both the endogenous L-PK gene and the CAT 
gene by glucose were similar. 
2. Materials and methods 
2.1. Retroviral vector construction 
All plasmids were constructed by standard DNA cloning procedures. 
Junctions were checked by DNA sequencing. The construct pHSG- 
(L4L3)4-PKCAT, presented in detail in Fig.l, contains the MMLV 
constructive frame of pHSGneo and CAT gene coding sequence di- 
rected by the rat L-type pyruvate kinase gene promoter (bp -119 to 
+ 11) upstream of which four repeats of the L4-L3 fragment (i.e. GIRE 
and contiguous HNF4 binding site) were ligated. L4-L3 fragment, 
covering bp -172 to -123 upstream of the L-PK transcription start site, 
was obtained by PCR [2]. The polyA signal sequence used was that 
present in the 3'-LTR of MMLV. pHSGneo [15], a MMLV-based 
retroviral plasmid, and (0CRIE an amphotropic packaging cell line 
which supplies the structural proteins of MMEV in trans, were pro- 
vided by Dr. A. Weber (Institut Cochin de G6n6tique Mol6culaire, 
Paris); pRSVneo, in which aminoglycoside-phosphotransferase g ne 
was driven by the Rous Sarcoma Virus LTR promoter, was used for 
cotransfection. 
2.2. Cell culture and transfection 
The hepatocyte-like cell line mhAT3F was derived from the tumoral 
liver of transgenic mice expressing the SV40 early gene driven by the 
liver-specific antithrombin III promoter (ATIII-SV40) [12,13]. These 
cells were cultured in DMEM/NUT.MIX. FI2 (1 : 1 vol/vol) with gluta- 
max-1 or DMEM/HamF12 (1 : 1 vol/vol)(Gibco-BRL) with or without 
D-glucose (Sigma), supplemented with 1 /tM dexamethasone, 1 ktM 
triiodothyronine, 20nM human insulin, 5% (vol/vol) fetal calf serum 
(FCS). NIH3T3 and ~0CRIP cells were cultured in DMEM (5.5 mM 
glucose, 1.0 mM sodium pyruvate) supplemented with 10% (vol/vol) 
newborn calf serum. Ampicilline, streptomycine and glutamine were 
added in all media and cultures were incubated at 37°C with 5% (vol/ 
vol) CO 2. ~0CRIP cells were cotransfected with pHSG(L4L3)4-PKCAT 
and pRSVneo (molar atio of the two plasmids i  10: 1) by the cationic 
liposome method (DOTAP, Boehringer Mannheim) and selected by 
G418 (800/lg/ml). G418 resistant clones were separated for the retro- 
virus production test. 
2.3. Viral RNA preparation and one-step RT-PCR 
G418-resistant clone cells were seeded in 90 mm dish and cultured 
to 100% confluence. The supernatant of culture cells was filtered 
through 0.22/l pore membrane, incubated with DNase I (10/lg/ml) at 
37°C for 30 min and then centrifuged at65,000 rpm for 20 min at 4°C. 
The retroviral RNA was extracted and purified from the pellet by 
proteinase K and phenol/chloroform, co-precipitated with tRNA. The 
sample was dissolved in diethylpyrocarbonate (DEPC)-treated water 
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containing 1mM dithiothreitol (DTT), 40 U RNasirdl00/21, and then 
used for one step coupled RT-PCR [1(~18]. The two primers used for 
amplification were: sense Gag, 5'-ACTCAAATGCCCAATGAAGT- 
C-Y, corresponding to the Gag region of MMLV (bp 1524 to 1544); 
antisense CAT, the 5'-TCAACGGTGGTATATCCAGAT-Y, corre- 
sponding to the coding region of the CAT gene (bp 35 to 15 with respect 
to the translation start site). Reverse transcription from the antisense 
PCR primer was catalyzed by 8 U AMV reverse transcriptase 
(Promega) for 1 h at 42°C and the subsequent PCR with 2.5 U Taq 
DNA polymerase (Gibco) was performed for 3540 cycles. The ampli- 
fied fragment was expected as a 440 bp-long containing part of the gag 
gene, 4 repeats of the L4-L3 element, he -119L-PK promoter and the 
first 69 bp of the CAT gene. When necessary, the RT-PCR fragments 
were cloned and sequenced. 
2.4. Infection by recombinant retrovirus, estimation of the retrovirus 
titres and CAT assays 
RT-PCR positive clones were used to infect the NIH3T3 cells to 
characterize the infectious capabilities of produced retroviruses: 1 ml 
supernatant of 100% confluent culture cells was used to infect the 
logarithmic growth NIH3T3 with 8 pg/ml polybrene. After 3 h incuba- 
tion the polybrene was diluted to 2 pg/ml with medium, and culture was 
continued for another 48 h. The genomic DNA of infected mhAT3F 
cells was extracted and used for PCR amplication using the same 
primers as those used for RT-PCR. Detection of the specific amplified 
fragment proved the integration of the retroviral sequences into the 
genome of infected cells. The retrovirus titre was appreciated by com- 
paring intensities of the amplified DNA bands from genomic DNA of 
infected NIH3T3 cells and from different dilutions of the retroviral 
vector (10:10 6 molecules). Clones which produced infectious retro- 
viruses were co-cultured with mhAT3F cells: a 60 mm dish, whose 
bottom was broken away and the brim smeared with silicone oil, was 
placed upside down to divide the 90 mm dish into two parts; the 
mhAT3F cells and retrovirus-producing cells were added in the center 
and the periphery respectively, being careful not to mix the two types 
of cells. When the cells are well attached onto the dish after 6 h incuba- 
tion, the small dish was taken out. The medium was changed for 
another 16 h incubation, then polybrene was added to 8 pg/ml, the cells 
were cultured for 48 h. CAT activity was measured by thin-layer chrom- 
atography [19] and quantitated in cpm by liquid scintillation. 
3. Results 
3.1. Recombinant retrovirus production 
Retroviral vector pHSG(L4L3)4PKCAT and pRSVneo were 
used to cotransfect the packaging cells 9CRIE  Seventy G418- 
resistant cell clones were analyzed. Eight RT-PCR positive 
clones showed the capability of producing infectious recombi- 
nant retroviruses determined by specific PCR amplification of 
the expected fragment from NIH3T3 genomic DNA.  Out of the 
eight, we analyzed two clones of retroviruses containing differ- 
ent internal promoter regions: as shown in Fig. 1, clone F6 
(5 x 104 infectious retrovirus/ml medium) produced a retrovirus 
with the complete promoter region (4 repeats of the L4--L3 
fragments), clone B8 (5 x 105 infectious retrovirus/ml medium), 
a retrovirus with a deleted promoter (retaining only one com- 
plete L4-L3 fragment and a small part of a second L3 box). 
Since the same deletion was found in the genomic DNA of 
retrovirus-producing clones, in the genomic RNA of recombi- 
nant retrovirus as well as in the genomic DNA of infected 
NIH3T3 and mhAT3F cells, the deletion occurred probably 
early during transfection of the packaging cells and integration 
of the plasmidic DNA into chromosomal DNA. 
Characterization of the retrovirus-producing clones by RT- 
PCR simplified the cloning procedure and permitted the detec- 
tion of any deletion between the PCR primers. In addition, 
measure of retrovirus titres is often difficult when recombinant 
retroviruses do not contain marker genes for selection or histo- 
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Fig. 1. Retroviral vector and recombinants. The pHSG(L4L3)- 
4PKCAT is a retroviral plasmid. The Clone F6 and Clone B8 are 
recombinant retroviral variants containing L-PK gene promoter-de- 
rived internal promoters. The hatched rectangle represents he MMLV 
LTR and the stippled box is the L4(G1RE) and L3(HNF4 binding site) 
elements of the L-PK gene promoter. The proximal L-PK gene pro- 
moter is shown as a shaded rectangle and the CAT gene, an open 
rectangle. MMLVsequences and polylinker are presented as double 
horizonal line and double oblique line, respectively. The arrow head 
above the YLTR indicates the enhancer deletion. The start site of 
transcription is shown by the +1 position. Positions of the primers used 
for PCR and RT-PCR amplification of the recombinant retrovirus 
sequence are the primer GAG in 5' and primer CAT in 3'. 
chemical analyses. Therefore, we estimated the viral titres by 
a semiquantitative RT-PCR using different dilutions of pHSG 
(L4L3)4PKCAT as standards. 
3.2. Dose- and time-dependent glucose induction of  the chimeric 
LPKICA T gene 
Rat hepatocyte-like c ll line mhAT3F maintains the capabil- 
ity to respond to glucose by a transcriptional ctivation of the 
L-PK gene and is therefore suitable to test any glucose respon- 
siveness of the CAT transgene transferred by the retroviral 
vector, and therefore the function of the L-PK G1RE in a 
retroviral context. However, mhAT3F cells were only poorly 
infectable by recombinant retroviruses (not shown). To en- 
hance the infection efficiency, we co-cultured the mhAT3F cells 
two times with the retrovirus-producing cells. The L-PK pro- 
moter expression is hepatocyte-specific and was not detected in 
,~CRIP packaging cells (not shown). A satisfying infection level 
was achieved by using clone B8, but not clone F6, whose titre 
is at least tenfold lower than of clone F8. 
As shown in Figs. 2 and 3, the expression of the L-PK/CAT 
transgene in the infected mhAT3F cells was well induced by 
glucose, with a half maximal induction obtained for 34  mM 
glucose and a maximal induction for 8 mM glucose. For higher 
glucose concentrations, CAT activity remained relatively sta- 
ble. In mhAT3F cells cultured with 17 mM glucose, L-PK gene 
induction was observed at the 8th hour of incubation, was 
half-maximal before the 24th hour and maximal at the 48th 
hour. 
4. Discussion 
Up to now, retroviral vectors have especially been used to 
direct stable unregulated expression of a transgene from retro- 
viral LTR or internal cellular promoters [20]. However, it has 
been shown that the regulatory regions of the phosphoenolpy- 
ruvate carboxykinase (PEPCK) gene transferred through a 
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Fig. 2. Dose-dependent glucose induction of LPK/CAT gene expression 
in mhAT3F cells. The mhAT3F cells infected by co-culture with the 
clone B8 were seeded at 105 cells per 90 mm dish and cultured for 72 h 
in media containing different concentrations of glucose. (A) Autora- 
diogram of the CAT activities. (B) Relative CAT activities 
(mean + S.D.). Values between 0 and 17 mM glucose are means of 
7 independent assays, values at 24 and 32 mM glucose are means of 
2 assays only. The CAT activity (cpm) without glucose was set as zero. 
The CAT activities were expressed as percentages of the CAT activity 
presented with 8 mM glucose (100%). 
retroviral vector ex vivo [21] and in vivo [22] could still confer 
a transcriptional stimulation by cyclic AMP and glucocorti- 
coids and inhibition by insulin on a reporter gene. We show, 
in this report, that the L-PK gene GIRE also functions in a 
retroviral context, being able to confer the glucose responsive- 
ness on a reporter gene. 
The dose-dependent glucose effect on the activation of the 
L-PK/CAT transgene in infected mhAT3F cells shows a half 
maximal activation at 3 ~,  mM glucose, which is lower than that 
in hepatocytes [23]. The reason could be, at least in part, the 
replacement in mhAT3F cells of the low affinity glucokinase by 
high affinity hexokinase isozymes [11,14]. Nevertheless, 
mhAT3F cells still synthesize the Glut-2 glucose transporter 
(Antoine et al., personal communication) whose affinity for 
glucose is relatively low (Km = 10 mM). This could be explain 
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why glucose concentration for a half maximal activation is 
intermediate in mhAT3F cells between that of hepatocytes and 
that expected for cells synthesizing the Glut-1 transporter and 
hexokinases 1 or 2 [24-26]. The time course of glucose-depend- 
ent activation of the transgene confirms that the phenomenon 
is relatively delayed in mhAT3F cells, as already reported for 
the endogenous L-PK gene and transfected L-PK/CAT plas- 
mids [14]. 
The major interest of the retroviral vector reported here, 
capable to transfer into hepatocytic cells a transgene positively 
regulated by glucose, is in the prospect of gene therapy for 
insulin-dependent diabetes mellitus (IDDM). Indeed, gene 
therapy using the insulin gene could transform ceils in vivo into 
insulin-secreting biopumps. Yet, these cells should be capable 
to express the insulin transgene under the control of physiolog- 
ical glucose concentration, which requires, among other condi- 
tions, that cell possess a glucose sensor system [26-28]. Such a 
A. 
B. 
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Fig. 3. Time course of LPK/CAT gene activation by glucose in 
mhAT3F cells. The mhAT3F cells infected by co-culture with clone B8 
were seeded at 105 cells per 90 mm dish and incubated for 72 h. 17 mM 
glucose was added in the media 72, 48, 24,16, 8, 4, 2 h, respectively, 
before harvesting the ceils. (A) Autoradiograms of the CAT activity. 
(B) Relative CAT activities (mean + S.D.). The CAT activity without 
glucose was set as zero and glucose induction during different periods 
were represented aspercentages of the value at the 48th hour set as 
100%. All values are means of three independent experiments. 
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system is composed of the Glut-2 glucose transporter and glu- 
cokinase. Only two cell types possess both activities, pancreas 
fl cells and hepatocytes [29,30]. Some genes expressed in the 
liver, in particular the L-type pyruvate kinase gene, are submit- 
ted to a physiological control by glucose. Therefore, it should 
be feasible to program hepatocytes to express the insulin gene 
under the same type of control. Since the unprocessed insulin 
gene product, proinsulin, is much less active than processed 
insulin, this strategy would require ither to modify the insulin 
gene to render it cleavable by the hepatocyte proteolytic ma- 
chinery [31,32], or to co-transfer into hepatocytes genes for 
pancreas fl cell-specific onvertases [33,34]. Infection of hepato- 
cytes by retroviral vectors can be made either ex vivo [21,35~0] 
or in vivo [22,41,42], resulting in both cases in the presence in 
the liver of some insulin-secreting cells. We can expect that 
insulin secretion i to the portal venous ystem, in which insulin 
is physiologically secreted under normal conditions, will be an 
advantage for this type of strategy. Besides, the lag period 
observed ex vivo between glucose signal and transcriptional 
activation of a transgene controlled by the L-PK regulatory 
region might not reflect the expression of the same transgene 
in vivo, which will be continuously stimulated by blood glucose. 
Reinstoration of an active insulin secretion by such a type of 
gene therapy, even though a normal glycoregulation may not 
be reinstored, should surely improve the symptoms of IDDM 
patient whoseendogenous pancreas insulin production isnil. A 
last. but not least, advantage of directing in vivo the insulin 
gene expression by the L-PK G1RE is that this sequence medi- 
ates an immediate blockage of gene transcription i hepato- 
cytes by glucagon (through cyclic AMP) [2,4]; therefore, an 
insulin transgene could be readily blocked at the transcriptional 
level by hyperglucagonemia secondary to hypoglycemia, which 
should avoid the risk of sustained hypoglycemia due to the 
surexpression f the insulin transgene. 
In conclusion, this paper demonstrates that it is feasible to 
use a retroviral vector to transfer into hepatocytic cells trans- 
genes activated by glucose. This result seems to be promising 
in the prospect of development of gene therapy for insulin- 
dependent diabetes mellitus. 
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